what makes daratumumab
We studied daratumumab, a CD38-targeting, human IgG1Îº monoclonal antibody, in a phase 1â2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.e studied daratumumab, a CD38-targeting, human IgG1Îº monoclonal antibody, in a phase 1â2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.